Streetbeat News

Earnings

HOWL

Werewolf Therapeutics, Inc. (HOWL) presented preclinical results at AACR 2024 showing anti-tumor effects of WTX-518 and WTX-712, engineered to stimulate the immune system for cancer treatment. WTX-518 led to complete tumor regressions in models, while WTX-712 showed potent antitumor activity with a unique immune activation mechanism. The company aims to develop these as immunotherapies for refractory or immunologically unresponsive tumors.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:32 pm

AAPL

AMZN

DIS

LLY

NKLA

XLE

Recent economic data and Federal Reserve officials' remarks have led investors to adjust expectations for interest rate cuts, as the U.S. economy shows resilience with job growth and manufacturing expansion. Energy stocks, particularly the Energy Select Sector SPDR Fund, benefited from rising oil prices. Apple is refocusing on home robotics, potentially entering a new market. Disney's board received strong shareholder support, affirming CEO Bob Iger's leadership. Eli Lilly faces supply challenges for its popular weight loss drugs on Amazon Pharmacy. Nikola Corp outperformed other EV stocks, including Tesla, Rivian, and Lucid, highlighting its recovery and focus on hydrogen fuel cell trucks.

Portfolio Pulse from Piero Cingari

April 05, 2024 | 8:23 pm

TDOC

Teladoc Health has announced that its outlook for the quarter ended March 31 and the year ending December 31, 2024, will align with the forecasts previously disclosed in its earnings release on February 20, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:14 pm

BPT

BP Prudhoe Bay Royalty Trust (NYSE:BPT) announced there will be no dividend payment for Q1 2024 due to the average daily closing WTI price being below the break-even price, resulting in a negative value for the payment calculation. The average Per Barrel Royalty was calculated as -$15.28, with average adjusted chargeable costs and production taxes contributing to the shortfall.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:12 pm

ME

23andMe Holding Co. (NASDAQ:ME) will present data on two clinical stage immuno-oncology programs at the AACR Annual Meeting 2024. The programs include 23ME-01473, targeting ULBP6, and 23ME-00610, targeting CD200R1. Both programs aim to enhance anti-tumor immunity, with '1473 focusing on restoring NK and T cell function and '00610 targeting the CD200R1 pathway for potential combination therapies. The presentations will showcase the discovery, preclinical data, and ongoing clinical trials for these antibodies.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:06 pm

SLB

Investors have shown a bearish stance on Schlumberger (NYSE:SLB), with options trading indicating a split sentiment of 42% bullish and 57% bearish. Significant options activity has been detected, with a focus on a price band between $25.0 and $57.5. Schlumberger, the world's largest oilfield service firm, is currently trading at $54.5, with an anticipated earnings release in 14 days.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 8:01 pm

MA

Mastercard (NYSE:MA) has seen significant options trading activity, with a mix of bullish and bearish sentiments among investors. Analysis of 17 trades reveals 41% bullish and 58% bearish positions, with options targeting a price range of $420.0 to $500.0. Notable trades include both calls and puts with varying sentiments and strike prices. Mastercard, a major payment processor, has seen its stock price increase by 1.43% to $476.49, with analysts giving an average target price of $525.0. The next earnings report is expected in 20 days.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 8:00 pm

TW

Tradeweb Markets (NASDAQ:TW) has received mixed analyst ratings in the last three months, with a total of 4 ratings ranging from bullish to somewhat bullish. The average 12-month price target for TW has been raised to $117.25, indicating a 7.82% increase from the previous target. Analysts from Citigroup, Morgan Stanley, and Rosenblatt have raised their price targets, reflecting positive sentiment towards the company's performance. Tradeweb Markets, a leading fixed-income trading platform, has shown strong financial metrics including a revenue growth rate of 26.26%, a net margin of 24.11%, and impressive ROE and ROA figures.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 8:00 pm

RPM

Recent analyst ratings for RPM International Inc (NYSE:RPM) show a mix of bullish to bearish sentiments, with an updated average 12-month price target of $125.29, reflecting a 4.85% increase from the previous target. The company's financial performance indicates strong market position, revenue growth, and profitability, despite a high debt-to-equity ratio. Analysts from firms like UBS, BMO Capital, Mizuho, and Baird have updated their ratings and price targets, reflecting their views on RPM's market performance.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 8:00 pm

STAA

STAAR Surgical's shares have seen an increase following the company's announcement of strong preliminary net sales guidance for the first quarter.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 7:50 pm